These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16166193)

  • 1. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?
    Haddad PM; Pal BR; Clarke P; Wieck A; Sridhiran S
    J Psychopharmacol; 2005 Sep; 19(5):554-7. PubMed ID: 16166193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine and neonatal withdrawal syndrome.
    Pogliani L; Schneider L; Dilillo D; Penagini F; Zuccotti GV
    BMJ Case Rep; 2010 Apr; 2010():. PubMed ID: 22736561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged neonatal complications after in utero exposure to fluoxetine.
    Alehan F; Saygi S; Tarcan A; Gürakan B
    J Matern Fetal Neonatal Med; 2008 Dec; 21(12):921-3. PubMed ID: 18985556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
    Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
    J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.
    Sanz EJ; De-las-Cuevas C; Kiuru A; Bate A; Edwards R
    Lancet; 2005 Feb 5-11; 365(9458):482-7. PubMed ID: 15705457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
    Gentile S; Bellantuono C
    J Clin Psychiatry; 2009 Mar; 70(3):414-22. PubMed ID: 19254517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy.
    Boucher N; Bairam A; Beaulac-Baillargeon L
    J Clin Psychopharmacol; 2008 Jun; 28(3):334-9. PubMed ID: 18480693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.
    Murray KL; Miller KM; Pearson DL
    J Perinatol; 2007 Aug; 27(8):517-8. PubMed ID: 17653218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?
    Isbister GK; Dawson A; Whyte IM; Prior FH; Clancy C; Smith AJ
    Arch Dis Child Fetal Neonatal Ed; 2001 Sep; 85(2):F147-8. PubMed ID: 11561552
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
    Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
    Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withdrawal syndromes after paroxetine and sertraline discontinuation.
    Fava GA; Grandi S
    J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
    [No Abstract]   [Full Text] [Related]  

  • 13. Neonatal paroxetine withdrawal syndrome.
    Stiskal JA; Kulin N; Koren G; Ho T; Ito S
    Arch Dis Child Fetal Neonatal Ed; 2001 Mar; 84(2):F134-5. PubMed ID: 11207233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.
    Knoppert DC; Nimkar R; Principi T; Yuen D
    Ther Drug Monit; 2006 Feb; 28(1):5-7. PubMed ID: 16418684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal outcome following third trimester exposure to paroxetine.
    Costei AM; Kozer E; Ho T; Ito S; Koren G
    Arch Pediatr Adolesc Med; 2002 Nov; 156(11):1129-32. PubMed ID: 12413342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review].
    Agut-Quijano T; Martínez-Nadal S; Elizari-Saco MJ; Sala-Castellví P; Vila-Cerén C; Raspall-Torrent F
    Rev Neurol; 2006 Jun 1-15; 42(11):660-2. PubMed ID: 16736401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal convulsions secondary to paroxetine withdrawal.
    Ahmed M; Parameshwaran A; Swamy P
    J Pak Med Assoc; 2007 Mar; 57(3):162. PubMed ID: 17432029
    [No Abstract]   [Full Text] [Related]  

  • 18. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
    Nordeng H; Lindemann R; Perminov KV; Reikvam A
    Acta Paediatr; 2001 Mar; 90(3):288-91. PubMed ID: 11332169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse effects of selective serotonin reuptake inhibitors use during the third trimester of pregnancy and prevention guidelines].
    Mejías C; Rodríguez-Pinilla E; Fernández Martín P; Martínez-Frías ML
    Med Clin (Barc); 2007 Apr; 128(15):584-9. PubMed ID: 17462198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
    Prescrire Int; 1999 Oct; 8(43):157-9. PubMed ID: 11503843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.